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Device Advice  
 
Washington University School of Medicine 
 in St. Louis 
June 24, 2011 
 
Lynn Henley, M.S., M.B.A. 
Investigational Device Exemption (IDE)  
and Humanitarian Device Exemption (HDE) Programs 
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Objectives Today 
 
 IDEs:  When is an IDE necessary? 
 Transitional Devices 
 What is a Pre-IDE? 
 HDEs:  Requirements for Humanitarian 
Device Exemptions (HDEs) 
 Off-label Use of HDEs 
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Regulatory Requirements for Clinical 
Studies of Medical Devices 
 Informed Consent and Human Subject 
Protections 
 Institutional Review Board oversight 
 Financial Disclosure 
 Investigational Device Exemption (IDE) 
application   





 To encourage discovery and 
development  of useful medical devices 
for human use, to the extent consistent with 
the protection of the public health and 
safety and with ethical standards, while 
maintaining optimum freedom for scientific 
investigators in their pursuit of that purpose 
 




 Is still in the developmental stage 
 Object of a clinical investigation is to 
determine safety and efficacy  
 Is not considered to be in commercial 
distribution 
Investigational Use 
 Clinical evaluation of an already legally 
marketed device for a new intended use 
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Provisions of the IDE Regulation 
 All clinical investigations subject to IDE 
regulations must be approved before they can 
begin         
 Assigns responsibilities to all participants in clinical 
investigation       
 All subjects in the investigation must give written 
informed consent  
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Studies Subject to Device 
Regulation 
 
 If used to support a marketing application:                  
PMA, HDE or 510(k), OR 
 
         
 Collection of safety and effectiveness 
information (for a new intended use of a legally 
marketed device, etc.), OR 
 
 Sponsor-investigator studies of unapproved 
devices or new intended use of approved device 
(even if no marketing application planned) 
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SR, NSR or Exempt? 
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    All Device Investigations 
Studies Exempt from 
the IDE Regulation 
21 CFR Part 812.2(c) 
Studies Subject to the 
IDE Regulation 
NSR Studies 
  Abbreviated Requirements 
  21 CFR Part 812.2(b) 
SR Investigations 
Full Requirements 
21 CFR Part 812 
SR, NSR, or Exempt? 
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Studies Exempt from Device 
Regulation (no IDE needed) 
 
 Marketed pre-1976 devices or transitional devices 
 510(k)-cleared and HDE- or PMA-approved devices,    
if used in accordance with approved label  
 In vitro diagnostic devices (many) 
 Consumer preference testing of marketed device 
 Combinations of legally marketed devices  
 Custom devices (NARROWLY defined) 
 Foreign Studies; Declaration of Helsinki 
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Pre-1976 or Transitional 
Devices 
 Federal Food, Drug and Cosmetic Act 
Section 520(l) 
 “Transitional Provisions for Devices 
Considered as New Drugs” 
 New versions of these devices are not 
exempt 
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Pre-1976 or Transitional 
Devices 
Points to consider: 
 Devices may have been reclassified 
 If significant risk, IDE would be 
necessary 
 If not significant risk, no IDE but 
subject to 21 CFR 812, 50 and 56 
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Pre-1976 or Transitional 
Devices 
 Some were classified: 
 Gauze 
 Adhesive Tape 
 Tampons 
 Dialysis Fluid 
 Denture Cushions 
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Pre-1976 or Transitional 
Devices 
 Others remain in Class III 
 Injectable Silicone 
 Absorbable Sutures 
 Absorbable Dusting Powders 
 Injectable Teflon 
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Standard of Care 
If a marketed product is used in 
accordance with approved labeling, no 
IDE is required. 
Off-label use, or practice of medicine, is 
appropriate when no protocol is 
involved. 
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If NOT Exempt from Device  
Regulation, then… 
 Need to assess whether proposed study of device is 
considered SIGNIFICANT RISK (SR), or 
NONSIGNIFICANT RISK (NSR) 
 IRBs can and do make this assessment most of the time 
 FDA can assist IRBs and/or investigators by making risk 
determinations; this determination is final 
 See IRB Information Sheet on SR/NSR: 
http://www.fda.gov/oc/ohrt/irbs/devices.html#risk 
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Significant Risk (SR) Study 
    
 
Presents a potential serious risk to the health, 
safety, and welfare of a subject and is:                                          
 an implant; or 
 used in supporting or sustaining human life; or 
 of substantial importance in diagnosing, curing, 
mitigating, or treating disease or preventing 
impairment of human health 
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Significant Risk (SR) Study 
Examples 
    
 • Evaluation of a marketed biliary stent for use 
in the peripheral vasculature 
• Evaluation of unapproved radiofrequency 
ablation device for treatment of primary 
hepatic neoplasia  
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Significant Risk IDEs  
 Sponsor submits application to FDA 
 FDA approves, conditionally approves or 
disapproves IDE within 30 calender days 
 Sponsor obtains IRB approval  
 After both FDA and IRB approve the 
investigation, study can begin 
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Non-Significant Risk IDEs  
 Sponsor presents protocol to IRB and a 
statement why investigation does not 
pose significant risk  
 If IRB approves the investigation as NSR, 
it can begin 
 Abbreviated IDE requirements (labeling, 
IRB, consent, monitoring, reporting, 
prohibition on promotion)  
 No IDE submission to FDA needed 
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Non-Significant Risk Study 
Examples  
 Most functional MRI studies 
 Study of non-invasive blood pressure 
measuring device 
 Electroencephalography studies 
 Studies of wound dressings 
 Contact lens studies 
 Studies of conventional laparoscopes 
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          Example 
 
A study is being  
performed to assess the  
tolerability  of  
“electropulsation”. Electrical  
pulses with increasing  
intensity will be applied to 
human nail until the subject 
feels mild discomfort.  
Answer: NSR  
Washington University in St. Louis 24 
         Example 
A study is proposed 
looking at the safety 
and effectiveness 
 of an cleared daily  
wear lens to be used  
as extended wear lens.  
The lens has undergone  
some design changes. 
 
Answer: SR 
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        Example 
  
       A study is proposed to 
determine the safety and 
effectiveness of a prostate 
tissue diagnostic test obtained 
by a prostate biopsy to 
diagnose prostate cancer 
 Answer: SR 
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       Example 
 A study looking at patient 
preference of color of a 
legally marketed tongue 
depressor- red, yellow, or 
white 
 
 Neither SR or NSR 
 Answer: Exempt 
Washington University in St. Louis 27 
Pre-IDE or Study 
Determination Inquiry 
 If an IRB is uncertain whether a study 
is exempt, significant risk or non-
significant risk, FDA will make a 
determination 
 Brief protocol, device description, and a 
description of intended population  
 FDA will issue a letter; the 
determination is final 
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Pre-IDE or Study 
Determination Inquiry 
 Appropriate review division 
 
 60-day turnaround time 
 
 Also appropriate for OUS studies 
even if no IDE is planned 
Washington University in St. Louis 29 
 What do ALL clinical studies of 
unapproved or investigational 
medical devices conducted in U.S. 
have in common? 
 
 Same basic applicable regulations 
REGARDLESS of whether sponsor is a 
manufacturer or clinical investigator 








Dual Role:  An individual who both 
initiates and actually conducts the study 
Dual Responsibilities:  Sponsor and Investigator 
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Sponsor Responsibilities 
 Ultimately LEGALLY responsible for: 
 IRB approval  
 Conduct and monitoring of study 
 Appropriate reporting to IRB and FDA  
 Device disposition 
 Investigator agreements 
 Informing other investigators as needed 
 Adequate record-keeping 
 Labeling 
 Prohibition of promotion/marketing   
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Investigator Responsibilities 
 Sign Investigator Agreement and Commit to: 
 Follow protocol, FDA regs, and IRB/FDA conditions 
of approval 
 Provide financial disclosure or certification to 
sponsor initially and updates 
 Obtain IRB Approval 
 Initial, for study changes, & at least annually  
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Investigator Responsibilities 
 812.140(a)(2) Investigator is responsible for: 
 
(2) Records of receipt, use or disposition of a device 
that relate to: 
(i) The type and quantity of the device, the dates of its 
receipt, and the batch number or code mark. 
(ii) The names of all persons who received, used, or 
disposed of each device. 
(iii) Why and how many units of the device have been 
returned to the sponsor, repaired, or otherwise 
disposed of.  
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Investigator Responsibilities 
 Conduct Study: 
 Obtain informed consent from subjects  
 Enroll subjects, follow protocol, collect data 
(fill out CRFs) 
 
 Submit required reports to IRB and sponsor 
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Monitoring 
 
 The act of overseeing the progress of a 
clinical trial and ensuring that it is 
conducted, recorded, and reported in 
accordance with the protocol, SOPs, GCP, 
and applicable requirements 
 Ongoing continuous process 
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DSMB v. Monitoring 
 
Data Safety Monitoring Board (DSMB) 
 
Monitoring is a different process than 
oversight of a Data Safety Monitoring Board 
 
Washington University in St. Louis 37 
Data Safety Monitoring Board 
(DSMB) 
 A group that reviews data from a trial 
 They advise the sponsor regarding the 
continuing safety of trial subjects  
 Evaluate data for continuing validity and 
scientific merit 
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Monitor 
   An individual designated by a sponsor or     
  contract research organization to oversee  
  the progress of an investigation 
 
  Must be qualified by training and 
experience to monitor the investigation  
 
–  21 CFR 812.3(j) & 21 CFR 812.43(d) 
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Purpose of Monitoring 
 
 Protect human subjects 
 
 Ensure reliability of the data 
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Monitors Inspect 
 
 IRB approvals  
 Informed Consent Documents 
 Case Report Forms (CRF) 
 Source documents 
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Monitoring 
 Does the sponsor-investigator need to 
ensure adequate monitoring of the 
investigation at his/her own site? 
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Monitoring 
          
 
 
                        Yes. 
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Required Elements of an IDE 
 U.S. Sponsor (manufacturer or investigator)  
 Prior Investigations     
 Investigational Plan     
   
 Manufacturing Information    
  
 Investigator and IRB Information   
  
 Sales Information 
 Labeling 
 Informed Consent 
 21 CFR 812.20  
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21 CFR Part 56:  IRBs   
 Extremely important role in the protection 
of rights, safety and welfare of human 
research subjects 
 Study risk determinations 
 Specific constitution of diverse members 
(scientists, physicians, clergy, laypeople, 
attorneys) 
 Review protocols, adverse events 
 Lots of guidance from FDA and HHS 
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IRB Responsibilities 
 Determine jurisdiction 
 FDA, NIH,“basic physiologic research” 
 Determine the risk 
 Minimal risk (expedited IRB procedures) 
 NSR or SR (unless FDA has already decided) 
 Review study 
 Approve, approve w/modifications, table 
pending additional information, disapprove 
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IRB Responsibilities 
 Review informed consent 
 For SR device trials, FDA has reviewed for 
compliance w/section 50.25   
 Review study changes & adverse events;   
do continuing review 
 Submit reports to sponsor & FDA 
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Custom vs. IDE Device 
 Custom device: 
 One device which deviates from devices generally 
available or from premarket approval requirements 
to comply with requirements of an individual 
physician for a specific patient 
 IDE device: 
 Investigational or experimental 
 May be customized to fit an individual patient  
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Custom vs. IDE Device 
 Custom device: 
 Is not generally available to or generally used by 
other physicians – one device 
 Made for a specific use in a specific situation 
 Many devices are routinely sized for individual 
patients; however, they are not custom devices 
 
 IDE device: 
 Available in a clinical trial setting for multiple 
subjects 
 May be customized to fit a specific patient (e.g., 
dental devices, orthopedic devices 
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Custom vs. IDE device 
 Very few devices/situations meet the definition 
of custom! 
 
 Questions:  Check with CDRH Office of 
Compliance or Office of Device Evaluation 
(IDE/HDE Staff)   
 






Humanitarian Use Devices (HUDs) 
and                                                  
Humanitarian Device Exemptions 
(HDEs) 
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Section 520(m) of the  
Food, Drug and Cosmetic Act 
  “… to encourage the discovery and use of   devices 
intended to benefit patients in the treatment and 
diagnosis of diseases or conditions that affect fewer 
than 4,000 individuals in the United States.” 
[yearly] 
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Intent of HDE Provisions 
Provide incentive for development of devices  
intended for treatment or diagnosis, in small  
patient populations where otherwise a  
device manufacturer’s R&D costs could  
exceed market returns 
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Statutory Conditions 
 Device not otherwise available (through a 510(k) 
or PMA)  
 No comparable device available (through a 
510(k) or PMA)  
 Device: 
 Does not pose unreasonable risk of illness  or injury 
[i.e., safety is demonstrated],  AND 
 Probable benefit outweighs the risk (i.e., exempt 
from effectiveness requirements of a PMA) 
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Statutory Conditions 
 Approval (HDE) authorizes marketing of HUD 
 IRB approval required before the device is used   
 Local IRB may approve or defer 
 Labeling must clearly identify device as HUD, and 
that effectiveness for that indication has not been 
demonstrated 
 Amount charged cannot exceed cost of research, 
development, manufacturing and distribution, 
except for devices with pediatric indications 
(FDAAA 9/2007) 
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FDA Approval Threshold 
Device does not expose patients to 
unreasonable risk of illness or  
injury, AND probable benefit 
outweighs the risks of using the  
device, taking into account the  
probable risks and benefits of  
alternative therapies 
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Examples:  Two Fetal Bladder Stents 
(Double pigtail stent with trocar & 
guidewire) 
 
Used in fetal urinary tract decompression following the 
diagnosis of fetal post-vesicular obstructive uropathy 
in fetuses of 18 to 32 weeks gestational age. 
 Alternative Therapies 
 Repeated needle aspirations 
   of fetal bladder 
 Open fetal surgery  
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            Example:  Heart Valve  
(Surgically implanted bovine jugular vein 
with a competent tri-leaflet venous valve) 
 Indicated for correction or 
    reconstruction of the Right Ventricular Outflow 
Tract (RVOT) in patients aged less than 18 years 
    with congenital heart malformations such as 
pulmonary stenosis and Transposition with 
Ventricular Septal Defect (VSD) 
 Alternative Therapies 
 Homografts 
 Polyester conduits 
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 Chronic, intractable nausea and/or 
vomiting secondary to 
gastroparesis 
 Alternative Therapies 
 Drugs 
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Medically Plausible Subset 
 
If the disease or conditions occurs in >4,000 
patients per year, the device could be used in a 
subset of the disease or condition  
AS LONG AS sponsor shows 
the subset is medically plausible (NOT just "readily 
identifiable“).   
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Medically Plausible Subset 
A medically plausible subset is one in 
which use of the device is limited to that subset 
because of some inherent property of the 
device  
and/or the disease.  That is, the sponsor must  
explain why the device couldn't also be used in 
all patients with disease or condition.  
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HUD Designation 
(21 CFR 814 Subpart H) 
 Request submitted to FDA’s Office of 
Orphan Products (not CDRH) 
 Designates the intended population for the 
device 
 Must be <4000/year in the U.S. 
 If subset of a larger population, must be 
“medically plausible” subset 
 45 day review 
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HDE Review by CDRH 
 Ensure HUD designation has first been 
granted from Office of Orphan Products  
 Explanation why device would not otherwise 
be available 
 Statement that no comparable device exists 
 Amount charged (can recover R&D, 
manufacturing and distribution)  
 Device description 
 No user (MDUFMA) fee 
 75 days 
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HDE Review by CDRH 
 Bench and animal testing 
 Clinical experience:  data, literature, 
investigation(s), marketing experience 
 Manufacturing information: QSR applies 
(unless elements waived) 
 Labeling (physician and patient), 
including HUD statement (that no 
effectiveness demonstrated) 
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Points of Confusion 
 HDE devices are marketed, NOT 
investigational, devices 
 Informed consent is not an FDA 
requirement, but can be (and often is)        
a state, local, institutional or IRB 
requirement 
 A clinical trial for a new indication requires 
an IDE for SR devices (so far, all HDEs are 
SR) 
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 52 approved HDEs since 1996 
 List of approved HDEs and their Summaries 
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Please Note 
 Use of HDE device once approved is not 
necessarily limited to the HDE indication (IRB 
can approve “off-label” use) 
 Device may also have other different HDE- or 
PMA-approved indications 
 Can have multiple HDEs for the same 
indication, but once any device is PMA-
approved for same indication, FDA may 
rescind HDEs (due to comparable device) 
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Off-label Use of HDE-Approved Products 
 Individual IRBs may: 
 Disapprove any use of the HDE 
 Approve only on a case by case basis 
 Approve only for “on-label” use 
 Approve for “on-label” use and case by case 
for “off-label” use 
 Approve for ANY use, on- or off-label 
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Responsibilities for HDE Holders 
 Maintain records of names and 
addresses of facilities to which HUD is 
shipped, correspondence with IRBs, and 
any other information required by 
reviewing IRB or FDA  
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Key Points 
  HDE is marketing approval 
  IRB approval required 
  Informed Consent not required by FDA 
  No requirement to submit PMA 
  Can have multiple HDEs for same    
    indication from different sponsors 
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HDE vs. PMA 
 Both marketing approvals 
 Approval thresholds differ: 
 PMA: safety and effectiveness 
 HDE: safety and probable benefit 
 IRB approval required for shipping HDE  
 Profit not allowed for HDE, except pediatric indication 
(can recover costs of R&D, manufacturing and 
handling) 
 No MDUFMA user fees for HDE application 
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Off-label or Compassionate Use 
 HDEs are marketed products 
 Section 906 of the FD&C Act states: 
“Nothing in this Act shall be construed to 
limit or interfere with the authority of a 
health care practitioner to prescribe or 
administer any legally marketed device to a 
patient for any condition or disease within 
a legitimate health care practitioner-patient 
relationship...” 
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Off-label or Compassionate Use  
 Prior FDA approval is not needed for 
off-label use of a HUD if it is being used 
in the practice of medicine and not for 
investigational use 
 IRBs need to determine whether or not 
they will approve off-label use of HUDs 
in their facility. 
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Off-label or Compassionate Use 
 
 If data will be collected on the “off-
label” use for research, publication, 
etc., it is considered an investigational 
use, and requires an IDE 
 To date, all approved HDEs have 
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FDAAA and IRBs 
Section 303c:  
FDA will issue guidance for institutional review 
committees on how to evaluate requests for 
approval for devices for which a humanitarian 
device exemption has been granted 
 
HDE Guidance 2010: 
http://www.fda.gov/MedicalDevices/DeviceRegulationan
dGuidance/GuidanceDocuments/ucm110194.htm 
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Resources 
 Information Sheet Guidance For IRBs, 
Clinical Investigators, and Sponsors 
 Frequently Asked Questions About 
Medical Devices 
 Significant Risk and Nonsignificant Risk 
Medical Device Studies   
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BIMO Questions? 
             
 
             Matt Tarosky 
 
             301-796-5645 
